TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
BofA Securities Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Raises Target Price to $15
B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $15
Amicus Therapeutics Is Maintained at Overweight by Morgan Stanley
Amicus Therapeutics Analyst Ratings
Morgan Stanley Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $18
Amicus Therapeutics Price Target Maintained With a $20.00/Share by Cantor Fitzgerald
Jefferies Initiates Amicus Therapeutics(FOLD.US) With Buy Rating, Announces Target Price $18
Amicus Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $16
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $16
Amicus Therapeutics Analyst Ratings
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics Inc: Wells Fargo launches insurance with an increase in holdings rating; target price is $18
Guggenheim: Amicus Therapeutics (FOLD.US) rating was raised, adjusted from neutral to buy, with a target price of $13.00.
Amicus Therapeutics Analyst Ratings
Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target
UBS Maintains Buy on Amicus Therapeutics, Lowers Price Target to $19
UBS: Maintains Amicus Therapeutics (FOLD.US) rating, adjusted from buy to buy rating, and adjusted target price from $20.00 to $19.00.
No Data
No Data